8-K
filed May 13, 2025, 7:59 PM ET
ticker ALLO
CIK 0001737287
earnings
confidence high
sentiment neutral
materiality 0.70
Allogene Q1 net loss $59.7M; ALPHA3 milestone delayed to 1H 2026; cash runway to 2H 2027
Allogene Therapeutics, Inc.
2025-Q1 EPS reported
-$0.28
- Net loss $59.7M ($0.28/sh); R&D $50.2M, G&A $15M; cash, equivalents & investments $335.5M.
- ALPHA3 (cema-cel) lymphodepletion/futility analysis shifted to 1H 2026; >250 patients consented, ~50 sites activated.
- ALLO-329 RESOLUTION basket trial in AID starts mid-2025; proof-of-concept data moved to 1H 2026.
- ALLO-316 TRAVERSE updated Phase 1b results to be presented at ASCO June 1, 2025.
- Cash runway extended into 2H 2027; 2025 guidance: cash burn ~$150M, GAAP op ex ~$230M.
Machine-readable event card
- schema_version
- secwatch.filing_event.v1
- accession
- 0001737287-25-000063
- form_type
- 8-K
- ticker
- ALLO
- cik
- 0001737287
- company_name
- Allogene Therapeutics, Inc.
- filed_at
- 2025-05-13T23:59:59+00:00
- discovered_at
- 2026-05-14T18:02:49.518181+00:00
- generated_at
- 2026-05-21T16:53:17.541256+00:00
- sec_items
- ["2.02", "9.01"]
- event_type
- earnings
- sentiment
- neutral
- materiality_score
- 0.7
- calibrated_materiality_score
- 0.7
- confidence
- high
- secwatch_canonical_url
- https://secwatch.observer/filing/0001737287-25-000063
- json_url
- https://secwatch.observer/filing/0001737287-25-000063.json
- markdown_url
- https://secwatch.observer/filing/0001737287-25-000063.md
- text_url
- https://secwatch.observer/filing/0001737287-25-000063.txt
- edgar_index_url
- https://www.sec.gov/Archives/edgar/data/1737287/000173728725000063/0001737287-25-000063-index.htm
- edgar_primary_document_url
- https://www.sec.gov/Archives/edgar/data/1737287/000173728725000063/allo-20250513.htm
- generated_by_model
- deepseek-v4-flash:cloud@v2
- review_status
- machine_generated
- human_reviewed
- false
- corrected
- false
- correction_note
- null
- correction_timestamp
- null
- superseded_by
- null
Comparable filings
GMRS
GMR Solutions Q1 revenue $1.46B (+6.6% YoY), net income $106M (+180% YoY), guides FY26 rev $5.9-6.2B
GMR Solutions Inc.
June 1, 2026, 4:45 PM ET
earnings
Items 2.02, 9.01
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
Filing page
SEC filing
DAVEY TREE EXPERT CO
Davey Tree Q1 net loss widens to $10.7M; revenue flat at $435.8M
DAVEY TREE EXPERT CO
June 1, 2026, 1:50 PM ET
earnings
Items 2.02, 9.01
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
Filing page
SEC filing
RMCF
Rocky Mountain Chocolate Factory Q4 revenue down 24% to $6.8M; net loss per share widens to $0.38
Rocky Mountain Chocolate Factory, Inc.
June 1, 2026, 9:15 AM ET
earnings
Items 2.02, 9.01
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
Filing page
SEC filing
FNGR
FingerMotion FY2026 revenue down 32% to $24.1M; net loss widens to $7.0M
FingerMotion, Inc.
May 29, 2026, 5:12 PM ET
earnings
Items 2.02, 7.01, 9.01
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
Filing page
SEC filing
BKE
Buckle Q1 net income $46.9M ($0.93/share), sales up 6.1% to $288.7M
BUCKLE INC
May 29, 2026, 3:38 PM ET
earnings
Items 2.02, 9.01
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
Filing page
SEC filing
HIND
Vyome Q1 net loss $963K, cash $8.8M, inks JAK inhibitor licensing deal with Impetis
Vyome Holdings, Inc
May 29, 2026, 8:42 AM ET
earnings
Items 2.02, 9.01
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
Filing page
SEC filing
ELMT
Elmet Group Q1 revenue up 21% to $56M; adjusted EBITDA +106% to $9.2M; record backlog $113M
Elmet Group Co.
May 29, 2026, 8:05 AM ET
earnings
Items 2.02, 9.01
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
Filing page
SEC filing
GCO
Genesco reports Q1 sales beat, raises FY2027 EPS outlook; launches $40-50M cost program
GENESCO INC
May 29, 2026, 7:07 AM ET
earnings
Items 2.02, 9.01
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
Filing page
SEC filing
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.